Sentence examples for major bleeding incidences from inspiring English sources

In the double blind ROCKET-AF trial patients on rivaroxaban 20 mg od had reduced rates of stroke and systemic embolism and comparable major bleeding incidences compared to warfarin [ 3].

Although no difference was found as to major bleeding events, overall bleeding incidence (key safety end point) showed a dose-dependent trend in the atopaxar arm as compared with placebo by CURE criteria (p for trend=0.01) but not by TIMI criteria (p for trend=0.07).

In the double blind ARISTOTLE trial, apixaban was associated with lower rates of strokes and major bleeding and reduced incidence of cardiovascular deaths compared to warfarin [ 4].

Higher simplified PESI scores were associated with higher incidences of major bleeding and all-cause mortality; the cumulative incidences of these events according to the simplified PESI are shown in Figures 1C and 1D.

In initial validation studies, a score of 1 was associated with a 0.83 % yearly incidence of major bleeding events, whereas a score >5 was associated with an incidence of 16.6 % per year [ 27].

The incidences of major bleeding (2.0% vs 2.4%), deaths (5.2% vs 4.4%), and thrombocytopenia (0.9% vs 1.2%) were also similar.

The primary safety outcomes were the incidences of major bleeding and death from all causes up to POD28.

Safety analysis showed that the incidences of major bleeding up to POD28 in patients undergoing TKA and THA were 1.2% (n = 15) and 2.3% (n = 20), respectively.

The incidences of major bleeding during the initial treatment period (1.1% vs 1.2%), deaths at 3 months (3.8% vs 3.0%), and thrombocytopenia (0.6% in each group) were also similar.

In patients with simplified PESI scores of 0, the incidences of major bleeding events were broadly similar between the two treatment groups at the different treatment periods; for the full treatment period, major bleeding occurred in 11 of the 1,254 patients (0.9%) in the rivaroxaban group and 16 of the 1,329 patients (1.2%) in the standard therapy group.

All have been demonstrated to be cost-effective in many countries for the health care system mainly based on the reduced incidence of major bleeding complications but also for some of the NOAC, due to a lower incidence of ischemic stroke and systemic embolism [ 5].